Khushi Quadri | Pharmacology | Best Researcher Award

Ms. Khushi Quadri | Pharmacology | Best Researcher Award

Research Scholar at SGT COLLEGE OF PHARMACY, India

Khushi Quadri is a passionate and driven researcher in the field of pharmaceutics, with a strong focus on nanotechnology, drug delivery systems, and biomedical applications. She has excelled academically, achieving an impressive 88.6% in her Master’s program at SGT University, Gurugram. Khushi has contributed extensively to the scientific community through publications in reputed journals such as Elsevier and iLiver. Her research spans diverse areas, including neurological disease treatments, biosensors, and eco-friendly nanomaterials. She has presented her work at several national and international conferences, showcasing her ability to effectively communicate complex scientific ideas. Khushi’s dedication to innovation and excellence has earned her recognition in competitions and tech fests. Alongside her academic and research pursuits, she has developed skills in teamwork, communication, and adaptability, making her a well-rounded professional.

Professional Profile

Education

Khushi Quadri has a robust academic foundation in pharmacy and pharmaceutics. She is currently completing her Master’s degree in Pharmaceutics at SGT University, Gurugram (2022-2024), where she has maintained an exceptional 88.6% score. Prior to this, she earned her Bachelor’s degree in Pharmacy from B.S. Anangpuria Institute of Pharmacy, Faridabad, achieving 75.7%. Her earlier education includes a solid performance in Class XII and Class X from Kalka Public School, Alaknanda, with scores of 86.8% and 76%, respectively. This strong educational background reflects her consistency and commitment to academic excellence.

Professional Experience

Khushi has actively engaged in professional academic and research activities. Her experience includes presenting posters at multiple international and national conferences, focusing on innovative topics like eco-friendly nanoparticles, biosensors, and drug delivery systems. She has also participated in numerous workshops, gaining hands-on knowledge in areas like tablet compression, coating techniques, and spectroscopy. Through these engagements, she has honed her research and presentation skills, enabling her to effectively contribute to the scientific community.

Research Interests

Khushi’s research interests lie at the intersection of pharmaceutics, nanotechnology, and biomedical sciences. She is particularly focused on green synthesis of nanoparticles for drug delivery and therapeutic applications, including neurological diseases and cancer treatment. Her work also explores the role of inorganic nanoparticles in water purification, biosensors, and antimicrobial therapies. Her commitment to sustainable research is evident in her studies on eco-friendly materials and their environmental impact.

Research Skills

Khushi Quadri possesses a diverse skill set that complements her research activities. She is proficient in designing and optimizing green synthesis techniques for nanoparticles and evaluating their biomedical applications. Her expertise extends to spectroscopic techniques, including FTIR and UV spectroscopy, and she has a strong grasp of Microsoft Excel and Word for data analysis and documentation. Additionally, her collaborative and adaptable nature allows her to effectively work in multidisciplinary teams, contributing innovative solutions to complex research challenges.

Awards and Honors

Khushi has been recognized for her academic and research excellence through several awards and honors. Notably, she secured 3rd rank in the Synergy Tech Fest 2023 for her project on eco-friendly mosquito repellents. She has also participated in various competitive events, including national conferences and debates, reflecting her proactive engagement with the academic community. Certificates of appreciation for her achievements in CBSE board exams and employability skills further underscore her dedication to personal and professional growth.

Conclusion 🎯

Khushi Quadri has demonstrated commendable achievements in academic performance, research, and conference participation, making her a strong candidate for early-career researcher recognition. However, for a Best Researcher Award, areas like deep specialization, innovation, international collaboration, and leadership experience may need further development.

Publication Top Notes

  1. New Approaches to the Treatment of Metabolic Dysfunction-Associated Steatotic Liver with Natural Products
    • Authors: P. Yadav, K. Quadri, R. Kadian, A. Waziri, P. Agrawal, M.S. Alam
    • Journal/Source: iLIVER
    • Year: 2024
    • Citation: P. Yadav, K. Quadri, R. Kadian, A. Waziri, P. Agrawal, M.S. Alam, “New Approaches to the Treatment of Metabolic Dysfunction-Associated Steatotic Liver with Natural Products,” iLIVER, vol. 100131, 2024.
  2. A New Era of Nanotechnology Applied in Neurological Disease Treatment
    • Authors: A.S.M.S.A. Jayamanti Pandit, Charu Bharti, Surbhi Gupta, Syed Muzammil Munawar
    • Book/Source: Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Insights
    • Year: 2024
    • Citation: A.S.M.S.A. Jayamanti Pandit, Charu Bharti, Surbhi Gupta, Syed Muzammil Munawar, “A New Era of Nanotechnology Applied in Neurological Disease Treatment,” in Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Insights, 2024.
  3. Potential Role of Probiotics in Neurological Disease Treatment
    • Authors: M.S.A. Khushi Quadri, Sagar Thakur, Sushma Chaturvedi, Renu Kadian, Geeta Rawat
    • Book/Source: Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Insights
    • Year: 2024
    • Citation: M.S.A. Khushi Quadri, Sagar Thakur, Sushma Chaturvedi, Renu Kadian, Geeta Rawat, “Potential Role of Probiotics in Neurological Disease Treatment,” in Essential Guide to Neurodegenerative Disorders: Mechanistic, Diagnostic and Therapeutic Insights, 2024.

 

JianYu Chen | Pharmacology | Best Researcher Award

Dr. JianYu Chen | Pharmacology | Best Researcher Award

Assistant Professor at Fujian University of Traditional Chinese Medicine, China.

Dr. JianYu Chen is an Associate Professor at Fujian University of Traditional Chinese Medicine, specializing in Pharmacodynamics and the mechanism of active components of Chinese medicine. She holds a Ph.D. in Chinese Medicine from Macao University of Science and Technology and has over five years of experience in academia. Dr. Chen’s research focuses on the treatment of autoimmune and inflammatory diseases using traditional Chinese medicine, with a particular emphasis on targeted inhibition of immune-inflammatory pathways and activation of antioxidant pathways for therapeutic purposes. She has received prestigious awards, including the Macao Special Administrative Region Graduate Science and Technology Research Award, and has published extensively in high-impact journals. Dr. Chen is committed to advancing the understanding and application of traditional Chinese medicine in modern healthcare.

Professional Profiles:

Education

Dr. JianYu Chen pursued her educational journey with a Bachelor’s degree in Chinese Pharmacy from Hubei University of Traditional Chinese Medicine (2007-2011). Building upon this foundation, she obtained a Master’s degree in Chinese Pharmacy from Fujian University of Chinese Medicine (2011-2014). Driven by a passion for research and academia, she further advanced her studies, earning a Doctoral degree in Chinese Medicine from Macao University of Science and Technology (2014-2018). Throughout her academic endeavors, Dr. Chen demonstrated a keen interest in pharmacodynamics and the mechanism of active components of Chinese medicine. Her educational path laid the groundwork for her impactful contributions to the field of traditional Chinese medicine.

Professional Experience

Dr. JianYu Chen has amassed valuable professional experience in the realm of academia and research. Commencing her career as a Lecturer at Fujian University of Chinese Medicine in September 2018, she contributed significantly to the academic environment. In December 2023, she elevated to the position of Associate Professor at the same institution, further solidifying her role in academia. Dr. Chen’s professional journey underscores her commitment to advancing knowledge and research in pharmacology, particularly in the domain of autoimmune and inflammatory diseases.

Research Interest

Dr. JianYu Chen’s research interests are primarily focused on pharmacodynamics and the mechanism of active components found in traditional Chinese medicine (TCM). She is particularly interested in exploring the effects and mechanisms of TCM active components in treating autoimmune and inflammatory diseases, such as rheumatoid arthritis, multiple sclerosis, and liver fibrosis. Her research endeavors aim to uncover novel therapeutic strategies derived from TCM that can effectively combat these debilitating conditions.

Award and Honors

Dr. JianYu Chen has garnered prestigious awards and honors in acknowledgment of her remarkable contributions to pharmacology and traditional Chinese medicine. Notably, she was awarded the Macao Special Administrative Region Graduate Science and Technology Research Award in 2018 for her groundbreaking research on active components from herbs against rheumatoid arthritis. This accolade, bestowed by the Macao SAR government, recognizes doctoral students who have significantly advanced knowledge in their field. Additionally, Dr. Chen received the Shanghai Plant Association Outstanding Paper Award in 2014 for her research on TCM active components against hypertrophic scars. These honors underscore Dr. Chen’s dedication to scientific inquiry and her innovative approach to addressing healthcare challenges through pharmacological research.

Research Skills

Dr. JianYu Chen possesses a diverse set of research skills honed through her extensive academic and professional experience in pharmacology and traditional Chinese medicine. Her expertise encompasses pharmacodynamics and the mechanisms of active components of Chinese medicine, with a focus on autoimmune and inflammatory diseases. Dr. Chen has demonstrated proficiency in experimental design, data analysis, and interpretation, enabling her to conduct impactful research in her field. She is adept at conducting literature reviews, experimental protocols, and statistical analyses to generate robust scientific evidence. Additionally, Dr. Chen has a strong background in molecular biology, cell culture techniques, and animal models, facilitating her investigations into the therapeutic potential of traditional Chinese medicine compounds. Her research skills enable her to contribute valuable insights to the understanding and treatment of inflammatory conditions, furthering advancements in pharmacology and healthcare.

Publications

  1. The function of sphingolipids in different pathogenesis of Alzheimer’s disease: A comprehensive review
    • Authors: Wang, X., Li, H., Sheng, Y., Qin, L., Meng, X.
    • Year: 2024
    • Citations: 2
  2. Network pharmacology-based study on mechanism of Zhi-Huang-Zhi-Tong powder in rheumatoid arthritis treatment 
    • Authors: Tian, X.-Y., Yang, Y.-J., Zheng, W.-T., Nan, L.-H., Chen, J.-Y.
    • Year: 2024
    • Citations: 0
  3. Exploring the therapeutic potential of natural compounds modulating the endocannabinoid system in various diseases and disorders: review
    • Authors: Wilson, G., Yang, L., Su, X., Chen, J., Ma, X.
    • Year: 2023
    • Citations: 0
  4. Corrigendum to “7-Deacetyl-gedunin suppresses proliferation of Human rheumatoid arthritis synovial fibroblast through activation of Nrf2/ARE signaling” [Int. Immunopharmacol. 107 (2022) 108557] (International Immunopharmacology (2022) 107, (S1567576922000418), (10.1016/j.intimp.2022.108557))
    • Authors: Chen, J., Zhu, G., Sun, Y., Ma, X., Zheng, Y.
    • Year: 2023
    • Citations: 0
  5. Corrigendum to “7-Deacetyl-gedunin suppresses proliferation of Human rheumatoid arthritis synovial fibroblast through activation of Nrf2/ARE signalling” [Int. Immunopharmacol. 107 (2022) 108557] (International Immunopharmacology (2022) 112, (S1567576922006646), (10.1016/j.intimp.2022.109180))
    • Authors: Chen, J., Zhu, G., Sun, Y., Ma, X., Zheng, Y.
    • Year: 2023
    • Citations: 0
  6. Magnolol as STAT3 inhibitor for treating multiple sclerosis by restricting Th17 cells
    • Authors: Chen, J.-Y., Tian, X.-Y., Wei, S.-S., Ma, X.-Q., Huang, M.-Q.
    • Year: 2023
    • Citations: 2
  7. Saikosaponin D alleviates cancer cachexia by directly inhibiting STAT3
    • Authors: Chen, L.-L., Xia, L.-Y., Zhang, J.-P., Guo, C., Xu, W.-H.
    • Year: 2023
    • Citations: 3
  8. Neobaicalein Inhibits Th17 Cell Differentiation Resulting in Recovery of Th17/Treg Ratio through Blocking STAT3 Signaling Activation
    • Authors: Chen, J.-Y., Yang, Y.-J., Ma, X.-Q., Zheng, Y.-F., Huang, M.-Q.
    • Year: 2023
    • Citations: 1
  9. Serum and brain metabolomic study reveals the protective effects of Bai-Mi-Decoction on rats with ischemic stroke
    • Authors: Yang, L., Su, X., Lu, F., Chen, J., Ma, X.
    • Year: 2022
    • Citations: 3
  10. Integration of pharmacodynamics and metabolomics reveals the therapeutic effects of 6-acetylacteoside on ovariectomy-induced osteoporosis mice
  • Authors: Liu, J., Ding, S., Yang, L., Chen, J., Ma, X.
  • Year: 2022
  • Citations: 3

Shriyansh Srivastava | Pharmacology Award | Best Researcher Award

Mr. Shriyansh Srivastava | Pharmacology Award | Best Researcher Award

Assistant Professor at Pharmacology Award, Galgotias University, India

Mr. Shriyansh Srivastava is a dedicated professional with a strong academic background and diverse expertise in the field of pharmacology and clinical research. Currently pursuing a PhD at Delhi Pharmaceutical Sciences and Research University, he previously completed his M. Pharm at ISF College of Pharmacy, where he achieved a CGPA of 8.54. With a B. Pharm from Dr. A.P.J. Abdul Kalam Technical University and a 12th-grade education from CRTS Vidya Mandir, Mr. Srivastava’s academic journey demonstrates his commitment to excellence. In addition to his academic achievements, Mr. Srivastava has been serving as an Assistant Professor at Galgotias University since August 31, 2021, focusing on the pharmaceutical field. He has attended various workshops and conferences, showcasing his dedication to continuous learning and professional development. His expertise includes operating advanced laboratory equipment such as the Langendroff Apparatus, fluorescent microscope, and centrifuge. He is also skilled in animal handling, histological studies, and using MS Office applications.

Professional Profiles:

Education:

Mr. Shriyansh Srivastava is currently pursuing a PhD in Pharmacology & Clinical Research at Delhi Pharmaceutical Sciences and Research University, New Delhi, India, from 2022 to the present. He completed his M. Pharm (Pharmacology) at ISF College of Pharmacy, Moga, Punjab, India, from 2019 to 2021, with a CGPA of 8.54. His B. Pharm was completed at Dr. A.P.J. Abdul Kalam Technical University, Lucknow, Uttar Pradesh, India, from 2014 to 2018, with a percentage of 74.82%. In 2013-2014, he completed his 12th grade at CRTS Vidya Mandir, Siswa, Maharajganj, Uttar Pradesh, India, with a percentage of 86.6%.

Professional Experience:

This information describes Mr. Shriyansh Srivastava’s current professional role as an Assistant Professor at Galgotias University. It specifies that he is part of the School of Medical and Allied Sciences, specifically in the Department of Pharmacy. The details include his start date, which is August 31, 2021, indicating the duration of his employment in this position. It also mentions his focus area, highlighting that his teaching and research activities are centered around the pharmaceutical field. Overall, this information provides an overview of his current professional responsibilities and academic focus within the university setting.

Award Participated:

Mr. Shriyansh Srivastava has actively participated in various workshops and conferences to enhance his professional knowledge and skills. He attended a workshop on advanced histopathological techniques using microtome, cryostat, and tissue processor in February 2021. He also presented at the International Conference on “Unlocking Challenges Innovations and Global Opportunities in Research Amidst COVID-19 Pandemic” in December 2020. Additionally, he participated in the 59th National Pharmacy Week 2020 organized by ISF College of Pharmacy, Moga, and attended a one-day international workshop on lung injury therapy in November 2019. He also participated in the 54th IHPA National conference on safe and effective medicine in September 2019 and the 31st Annual Conference of India Pharmacy Graduates Association in April 2017, showcasing his commitment to professional development and staying updated with the latest advancements in the field.

Skills:

Mr. Shriyansh Srivastava possesses a wide range of expertise in laboratory equipment and techniques. He is proficient in operating the Langendroff Apparatus, fluorescent microscope, centrifuge, non-invasive blood pressure apparatus, Eddy’s hot plate, plethysmometer, actophotometer, student organ bath, microtome, and cryostat. He also has experience in handling animals, particularly rats, mice, and guinea pigs. Additionally, he has a strong understanding of histological studies and is skilled in using MS Office applications (Word, Excel, PowerPoint). He is well-versed in safety requirements and laboratory management, ensuring a clean and safe workplace. Furthermore, he is knowledgeable about Windows operating systems and various application software such as ChemDraw, EndNote, and BioRender.

Publications:

  1. Unveiling the potential of proteomic and genetic signatures for precision therapeutics in lung cancer management
    • Authors: S Srivastava, N Jayaswal, S Kumar, PK Sharma, T Behl, A Khalid, …
    • Year: 2024
    • Citations: 7
    • Journal: Cellular Signalling 113, 110932
  2. The Global Monkeypox (Mpox) outbreak: a comprehensive review
    • Authors: S Srivastava, S Kumar, S Jain, A Mohanty, N Thapa, P Poudel, K Bhusal, …
    • Year: 2023
    • Citations: 7
    • Journal: Vaccines 11 (6), 1093
  3. Biodegradable electrospun scaffolds as an emerging tool for skin wound regeneration: A comprehensive review
    • Authors: D Sharma, S Srivastava, S Kumar, PK Sharma, R Hassani, HG Dailah, …
    • Year: 2023
    • Citations: 6
    • Journal: Pharmaceuticals 16 (2), 325
  4. Wnt/β-catenin antagonist pyrvinium rescues high dose isoproterenol induced cardiotoxicity in rats: Biochemical and immunohistological evidences
    • Authors: S Srivastava, S Yadav, G Singh, SS Bajwa
    • Year: 2022
    • Citations: 6
    • Journal: Chemico-Biological Interactions 358, 109902
  5. Evolution of β-catenin-independent Wnt–GSK3–mTOR signalling in regulation of energy metabolism in isoproterenol-induced cardiotoxicity model
    • Authors: S Srivastava, N Bagang, S Yadav, S Rajput, D Sharma, A Dahiya, …
    • Year: 2021
    • Citations: 5
    • Journal: Inflammation Research 70 (7), 743-747
  6. Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
    • Authors: S Dhoundiyal, S Srivastava, S Kumar, G Singh, S Ashique, R Pal, …
    • Year: 2024
    • Citations: 3
    • Journal: European Journal of Medical Research 29 (1), 26
  7. Emergence of Marburg virus: a global perspective on fatal outbreaks and clinical challenges
    • Authors: S Srivastava, D Sharma, R Rijal, S Adhikari, P Bashyal, JJ Barboza, …
    • Year: 2023
    • Citations: 3
    • Journal: Frontiers in Microbiology 14, 1239079
  8. Platelet‐rich plasma exhibits anti‐inflammatory effect and attenuates cardiomyocyte damage by reducing NF‐κB and enhancing VEGF expression in isoproterenol induced …
    • Authors: S Yadav, S Srivastava, G Singh
    • Year: 2022
    • Citations: 3
    • Journal: Environmental Toxicology 37 (4), 936-953
  9. Recent Nipah virus outbreak in India: lessons and imperatives
    • Authors: S Srivastava, N Deb, P Roy, V Jaiswal, S Sah, Y Pandey, …
    • Year: 2023
    • Citations: 1
    • Journal: Therapeutic Advances in Infectious Disease 10, 20499361231208535
  10. Significant progress in chikungunya Control: FDA approval of Ixchiq vaccine
    • Authors: S Srivastava, S Kumar, P Satapathy, KH Jaaaim, AH Hermis, R Mehta, …
    • Year: 2024
    • Journal: Clinical Infection in Practice, 100351